Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Nektar Therapeutics Market Cap
The Nektar Therapeutics (NKTR) share price is expected to increase by 360.78% over the next year. This is based on calculating the average 12-month share price estimate provided by 7 stock analysts who have covered NKTR. Price targets range from $1.3 at the low end to $7 at the high end. The current analyst consensus for NKTR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assigned NKTR 3 buy ratings, 3 hold ratings, and 1 sell ratings. This means that analysts expect Nektar Therapeutics to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NKTR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of NKTR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Yasmeen Rahimi Piper Sandler | Overweight | $7 | Initiates | Nov 4, 2024 |
| Robert Hazlett BTIG | Buy | $4 | Assumes | Sep 30, 2024 |
| Roger Song Jefferies | Hold | $1 | Maintains | Mar 6, 2024 |
| Jessica Fye JP Morgan | Underweight | Reinstates | Nov 20, 2023 | |
| Chris Shibutani TD Cowen | Outperform | Upgrade | Nov 9, 2023 | |
| Mara Goldstein Mizuho | Neutral | $6 | Reiterates | Aug 7, 2023 |
| Roger Song Jefferies | Hold | $1 | Upgrade | May 10, 2023 |
| Jay Olson Oppenheimer | Perform | $3 | Maintains | Mar 6, 2023 |
| Chris Shibutani Goldman Sachs | Sell | $2 | Maintains | Feb 27, 2023 |
| Daina Graybosch SVB Leerink | Market Perform | $3 | Maintains | Feb 24, 2023 |
| Roger Song Jefferies | Underperform | $1.5 | Downgrade | Feb 24, 2023 |
| Jessica Fye JP Morgan | Underweight | Downgrade | Aug 8, 2022 | |
| Roger Song Jefferies | Hold | $4 | Assumes | May 31, 2022 |
Goldman Sachs | Sell | Downgrade | Apr 18, 2022 | |
| Mara Goldstein Mizuho | Neutral | $6 | Maintains | Apr 18, 2022 |
| Daina Graybosch SVB Leerink | Market Perform | $6 | Maintains | Apr 18, 2022 |
| Arlinda Lee Canaccord Genuity | Buy | $6 | Maintains | Mar 16, 2022 |
Cowen & Co. | Market Perform | Downgrade | Mar 15, 2022 | |
| Mara Goldstein Mizuho | Neutral | $8 | Downgrade | Mar 15, 2022 |
BTIG | Neutral | Downgrade | Mar 15, 2022 |
When did it IPO
1994
Staff Count
137
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Howard W. Robin
Market Cap
$188.1M
In 2023, NKTR generated $90.1M in revenue, which was a decrease of -2.10% from the previous year. This can be seen as a signal that NKTR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sat, 07 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Nektar Therapeutics' NKTR-255 showed a 73% complete response rate in a Phase 2 study for R/R LBCL, compared to 50% for placebo, enhancing CAR T-cell efficacy post-treatment.
Why It Matters - Positive Phase 2 results for NKTR-255 indicate enhanced treatment efficacy for CAR-T therapy in lymphoma, potentially boosting Nektar Therapeutics' stock and market position.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Nektar Therapeutics presented promising preclinical data for NKTR-422, showing inflammation resolution and tissue repair, at the ACR conference in Washington, D.C., from Nov. 14-19, 2024.
Why It Matters - Positive preclinical results for NKTR-422 suggest potential breakthroughs in treating chronic inflammatory conditions, enhancing Nektar Therapeutics' value and growth prospects.
Thu, 14 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Nektar reports progress on rezpegaldesleukin, with phase 2 atopic dermatitis results due in H1'25. NKTR-255 shows promise in oncology trials and has a near-term update in the JAVELIN Bladder study.
Why It Matters - Nektar's advancements with rezpegaldesleukin and NKTR-255 could influence future revenue streams and market position, impacting stock performance amid competitive oncology landscapes.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Nektar Therapeutics (NKTR) held its Q3 2024 earnings call, providing updates on financial performance and strategic initiatives. Details on revenue and future guidance were discussed.
Why It Matters - Nektar Therapeutics' Q3 2024 earnings reveal financial health and operational performance, impacting stock valuation and future investment decisions.
Fri, 08 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - NKTR's third-quarter results exceeded expectations, with both earnings and revenues surpassing estimates and a year-over-year increase in product sales.
Why It Matters - NKTR's strong Q3 performance suggests growth potential, boosting investor confidence and potentially increasing stock value due to exceeding earnings and revenue expectations.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Nektar Therapeutics reported Q3 2024 financial results, showing cash and marketable securities of $249.0 million, down from $329.4 million at the end of 2023.
Why It Matters - Nektar Therapeutics' cash decline signals potential liquidity issues, impacting its ability to fund operations and R&D, which may affect stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
